Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1373254 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
Abstract
An erythromycin analogue, 11,12-di-O-iso-butyryl-8,9-anhydroerythromycin A 6,9-hemiketal (1b), was found to be a potential anti-MRSA and anti-VRE agent. The use of copper catalyzed azide–acetylene cycloaddition, and click chemistry, readily provided 10 types of triazole analogues of 1b in good to nearly quantitative yield. Among the library, 5b exhibited activity against MRSA and VRE bacterial strains, representing more than twice the potency of 1b.
Graphical abstractOne of 10 kinds of triazole compounds, the adamantyl-triazole product 5b, was produced as a potential lead of new antibiotic for use against MRSA and VRE strains, using click methodology.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Akihiro Sugawara, Toshiaki Sunazuka, Tomoyasu Hirose, Kenichiro Nagai, Yukie Yamaguchi, Hideaki Hanaki, K. Barry Sharpless, Satoshi Ōmura,